Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Protein farnesyltransferase inhibitors in development at Bristol-Myers Squibb

Feb. 19, 1999

Genzyme's oncology division in-licenses angiogenesis inhibitor for development

Feb. 19, 1999

Idec Pharmaceuticals announces three new cancer research collaborations

Feb. 19, 1999

CD-437, a novel retinoid compound targeted to the treatment of leukemia

Feb. 18, 1999

Specific inhibitors of MEK for cancer and other proliferative disorders

Feb. 18, 1999

Zarix in-licenses oncology drug from Agouron

Feb. 18, 1999

Initial findings reported for CollaGenex's anticancer compound

Feb. 17, 1999

Wistar Institute discovers mechanism of action of farnesyltransferase inhibitors

Feb. 17, 1999

First pivotal trial results reported for marimastat; BB to assess implications for development

Feb. 16, 1999

Available for licensing from NIH: BOG gene and protein product for Rx, Dx use

Feb. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...